tokens: While the only study we are aware of comparing TP53 mutation status in primaries and their distant metastases suggested an increasing fraction of tumors to express mutated TP53 during progression [ 78 ] , we do not know the potential contribution of either TP53 or CHEK2 mutations to drug resistance in micrometastases or in metastatic disease .